Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 06, 2020 07:30 ET | Source: Kaleido Biosciences

Kaleido Biosciences Provides Update on KB109 Clinical Data Timeline

LEXINGTON, Mass., Oct. 06, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), today announced an update to its ongoing COVID-19 clinical development program evaluating KB109 when...
October 01, 2020 07:30 ET | Source: Kaleido Biosciences

Kaleido Biosciences Appoints Daniel Menichella as President and Chief Executive Officer

LEXINGTON, Mass., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to targeting the microbiome to...
September 29, 2020 07:30 ET | Source: Kaleido Biosciences

Kaleido Biosciences Announces First Patient Dosed in Clinical Study of Microbiome Metabolic Therapy KB295 in Patients with Mild-to-Moderate Ulcerative Colitis

LEXINGTON, Mass., Sept. 29, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO) today announced that the first patient has been dosed in its clinical study evaluating Microbiome...
September 09, 2020 07:00 ET | Source: Kaleido Biosciences

Kaleido Biosciences to Present at Upcoming September Investor Conferences

LEXINGTON, Mass., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), today announced that Michael Bonney, Executive Chair, will participate in the following upcoming...
August 27, 2020 07:00 ET | Source: Kaleido Biosciences

Kaleido Biosciences Announces Presentation of Data for Microbiome Metabolic Therapy KB174 for Hepatic Encephalopathy at The Digital International Liver Congress™ (EASL)

LEXINGTON, Mass., Aug. 27, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO) today announced that data from Microbiome Metabolic Therapy (MMT™) candidate KB174 for hepatic...
August 05, 2020 08:00 ET | Source: Kaleido Biosciences

Kaleido Biosciences to Present at the Canaccord Genuity 40th Annual Growth Conference

LEXINGTON, Mass., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to targeting the microbiome to...
August 04, 2020 07:35 ET | Source: Kaleido Biosciences

Kaleido Biosciences Reports Second Quarter 2020 Financial Results and Provides Corporate Update

- COVID-19 Clinical Development Program Topline Data Readout of Multi-Center Study Expected in Q4 2020 - - Plan to Initiate New Clinical Study in Ulcerative Colitis in Q3 2020 - LEXINGTON, Mass.,...
July 23, 2020 07:00 ET | Source: Kaleido Biosciences

Kaleido Biosciences Initiates Controlled Clinical Study with Massachusetts General Hospital of Microbiome Metabolic Therapy KB109 in Outpatients with Mild-to-Moderate COVID-19

- Second Study Launched in Kaleido’s COVID-19 Clinical Development Program for this Rapidly Growing Patient Population - LEXINGTON, Mass., July 23, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences,...
June 16, 2020 16:45 ET | Source: Kaleido Biosciences

Kaleido Biosciences Announces CEO Leadership Transition

- Alison Lawton to step down as President and Chief Executive Officer to attend to a family health matter - The Board of Directors has established an Office of the CEO to manage the company through...
June 08, 2020 08:30 ET | Source: Kaleido Biosciences

Kaleido Biosciences Announces 2020 Annual Meeting of Stockholders to be Held as Virtual Meeting

LEXINGTON, Mass., June 08, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to targeting the microbiome to...